Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395441 · ClinicalTrials.gov registry record · Phase 3
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
A Phase 3 study of Malignant Solid Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 15
- Study locations
NCT06395441 is a Phase 3 study of Malignant Solid Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 160 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 1 state.
The verdict
NCT06395441, a Phase 3 study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Placebo Administration
- DIETARY_SUPPLEMENT American Ginseng
Study Locations (15)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Sanford Joe Lueken Cancer Center - Bemidji
- Essentia Health Saint Joseph's Medical Center - Brainerd
- Essentia Health Deer River Clinic - Deer River
- Essentia Health St. Mary's Detroit Lakes Clinic - Detroit Lakes
- Essentia Health Cancer Center - Duluth
- Essentia Health Fosston - Fosston
- Essentia Health Hibbing Clinic - Hibbing
- Mayo Clinic Health System-Mankato - Mankato
- MMCORC CentraCare Monticello Cancer Center - Monticello
- Mayo Clinic in Rochester - Rochester
- Essentia Health Sandstone - Sandstone
- Sanford Thief River Falls Medical Center - Thief River Falls
- Essentia Health Virginia Clinic - Virginia
- Sanford Worthington Medical Center - Worthington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06395441
The ClinicalTrials.gov registry entry for NCT06395441 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (86% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT06395441 reports 15 study locations spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06395441 about?
NCT06395441 is a clinical study titled "Wisconsin Ginseng for Decreasing Cancer Related Fatigue". This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaning...
What is the current status of trial NCT06395441?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2024-08-01. Estimated completion is 2026-11.
What conditions does trial NCT06395441 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm.
What interventions are being tested in trial NCT06395441?
The interventions under investigation include: Questionnaire Administration (OTHER), Placebo Administration (DRUG), American Ginseng (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06395441?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395441 being conducted?
This trial has 15 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · Phase 3
-
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
RECRUITING · Phase 3
-
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RECRUITING · Phase 3
-
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.